Trimethoprim-Sulfamethoxazole Effects on the Nasal Microbiome in Granulomatosis with Polyangiitis Study
Brief description of study
Trimethoprim-sulfamethoxazole (TMP-SMX; Bactrim) is an FDA-approved drug for the treatment of infections and commonly used for 2 weeks or less. The purpose of this study is to observe the changes in the microbiome in your nose before, during, and after taking TMP-SMX for 4 weeks. The extended duration of TMP-SMX used in this study was selected to better understand what type of changes occurred in the microbes or your nose and also the effects on your immune system.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Granulomatosis With Polyangiitis | Wegener Granulomatosis; GPA
-
Age: Between 18 Years - 99 Years
-
Gender: All
Updated on
02 Jul 2023.
Study ID: 831864
